EnterNext félicite Medical Device Works pour son introduction en Bourse sur NYSE Alternext

Back

Paris, 2 September 2013– EnterNext, the new NYSE Euronext subsidiary designed to develop and promote the market for SMEs, today announced the listing on NYSE Alternext in Paris of Medical Device Works, a pioneer in organ isolation technology used to treat malignant tumours.

Founded in 2004, Medical Device Works is developing a kit of minimally invasive devices used in surgery to temporarily isolate affected organs from the normal blood flow, allowing the chosen circuit to receive local chemotherapy at high concentrations. The company’s flagship product is PILP®, a system based on single-use catheters that can be combined with standard surgical kits. Medical Device Works aims to become an international standard-setter in cancer surgery.

Medical Device Works (ticker code: ALMDW) was listed through a private placement with qualified investors of 334,541 shares for €2.5 million. The admission price was €7.50 per share, and total market capitalisation on the day of listing was around €11.5 million.

Our autumn season is off to a strong start with the listing of Medical Device Works—a welcome addition to the pool of ambitious and innovative companies already present on NYSE Alternext, the organized market's benchmark for small and mid-sized companies,” said Eric Forest, EnterNext Chairman and CEO. “EnterNext is delighted to assist Medical Device Works at this decisive stage in its growth, at a time when PILP®, the company's flagship product, is gearing up to be licensed Europe-wide and is set to up-end the technologies used to fight liver cancer. Listing will boost the company's capacity to develop treatments for other high-mortality tumours.”

Hervé de Kergrohen, CEO of Medical Device Works, added "We are very proud to see our company listed on NYSE Alternext in Paris. Our technology—a unique approach designed to treat liver cancer more effectively by repeated isolation of the organ—has been developed with the support of our traditional shareholders and clinical partners. It will now benefit from the visibility offered by stock-exchange listing, which makes this an essential step for Medical Device Works, with a view to obtaining approval for CE marking in 2014.".

In eight years, €2.8 billion has been raised on NYSE Alternext, with half through secondary issues—by companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their market capitalisation totals over €6 billion. Today 187 companies are listed on NYSE Alternext.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.